Please login to the form below

Not currently logged in

VC raises new €270m fund for European biotechs

The money will mostly go to companies working on novel therapies

Life sciences venture capital company Forbion has raised €270m in funding for European biotechs, in a sign that investment cash is returning to the sector.

Sander SlootwegThe German-Dutch fund says the new fund – its fourth – was oversubscribed by around €20m and like its predecessors will go mainly (80%) to EU and UK companies working on novel therapies, medical devices and diagnostics, with the remainder looking at opportunities in North America.

Managing partner Sander Slootweg (pictured) – who will manage the new fund alongside Geert-Jan Mulder and Martien van Osch, said that the fund comes against a backdrop of “undersupply of capital for European development-stage life sciences investment”.

“We continue to see the opportunities for superior returns,” he asserted.

Forbion IV is a step up from its last fund, which raised €183m in 2016 with 70% earmarked for Europe companies, and takes the total managed by the company to almost €1bn. According to the VC it will have “an even sharper focus on biotech” and will be used to support around 15 companies, ideally ten in the growth phase a five brand new start-ups co-founded by Forbion. There could also be more to come, with the new fund not due to fully close until the autumn.

Forbion’s fundraising comes shortly after UK- and US-based VC Abingworth raised $315m for another oversubscribed fund destined for investments in early- to late-stage European and US life science companies.

Forbion has chalked up a number of successful exits from its earlier holdings, including the sale of Dezima Pharma to Amgen which netted €1.55bn and the $7bn takeover by AstraZeneca of Acerta, the developer of blockbuster-in-waiting acalabrutinib for lymphoma.

It currently has around 25 companies in its portfolio, including Dutch gene therapy specialist UniQure, UK women’s health start-up KaNDy Therapeutics and US biotech Argos Therapeutics which as an RNA-based kidney cancer drug candidate in late-stage testing.

With a surge of M&A deals involving biotech companies and big biopharma players already this year after a relatively quiet 2017, VC investors are seeing more opportunity to make money on lucrative exit deals. Ernst & Young predicted earlier this year that 2018’s biotech M&A tally will comfortably exceed last year’s $200bn value.

Forbion says its fourth fund will provide “substantial initial stakes of 20-50%, looking to take lead positions and work alongside entrepreneurial management teams” and that it already has a number of investment candidates in mind.

Article by
Phil Taylor

11th July 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....